Search Results - "Bernabe Caro, R"

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis by Borghaei, H., Ciuleanu, T.-E., Lee, J.-S., Pluzanski, A., Caro, R. Bernabe, Gutierrez, M., Ohe, Y., Nishio, M., Goldman, J., Ready, N., Spigel, D.R., Ramalingam, S.S., Paz-Ares, L.G., Gainor, J.F., Ahmed, S., Reck, M., Maio, M., O’Byrne, K.J., Memaj, A., Nathan, F., Tran, P., Hellmann, M.D., Brahmer, J.R.

“…First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical…”
Get full text

GECP 1605/NIVEX TRIAL nivolumab in the real world: The SPANISH expanded access program experience in pretreated advanced NSCLC by Majem Tarruella, M., Campillo, J., Grau Béjar, J.F., Carcereny, E., Bernabe Caro, R., Garcia, Y., Artal-Cortes, A., González Cao, M., Lianes, P., Paredes Lario, A., Sereno Moyano, M., Mielgo Rubio, X., Macias, J.A., Provencio Pulla, M., Rodriguez-Abreu, D.

Get full text

Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p) by Angelats, L., Garcia Campelo, M.R., Bernabe Caro, R., Arriola Aperribay, E., Calvo de Juan, V., Barba Joaquín, A., Vinolas Segarra, N., Gil Moreno, M.D.L.L., Vilà Martinez, L., Juan Vidal, O.J., Vilariño Quintela, N., Cobo, M., Sais, E., Domine Gomez, M., Fernandez Nuñez, N., Coves Sarto, J., Marse Fabregat, R., Esteve Gomez, A.M., Rodríguez-Abreu, D., Carcereny Costa, E.

Get full text

First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG) by Carcereny Costa, E., Rodriguez-Abreu, D., Guirado, M., López-Castro, R., Massutí, B., Bosch Barrera, J., Nogueron Martnez, E., Sala Gonzalez, M.A., Domine Gomez, M., Del Barco Morillo, E., Cerezo Gonzalez, S., Dorta Suarez, M., Casal Rubio, J., Camps, C., Muñoz, M.A., de las Peñas, R., Ortega dominguez, J.A., Gonzalez-Larriba, J.L., Bernabe Caro, R., Provencio Pulla, M.

Get full text

Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment by Herrero Rivera, D., Nieto-Guerrero Gómez, J. M., Cacicedo Fernández de Bobadilla, J., Delgado, D., Rivin del Campo, E., Praena-Fernández, J. M., Bernabé Caro, R., Ortiz Gordillo, M. J., Fernández Fernández, M. C., Lopez Guerra, J. L.

“…Purpose Chronic inflammation contributes to cancer development via multiple mechanisms. We hypothesized that cardiovascular diseases (CVD) are also an…”
Get full text

1101P Use of genomic sequencing for the determination of genomic alterations and new therapeutic opportunities in Spanish lung cancer (LC) patients (pts) by Garcia Campelo, M.R., Arriola, E., Isla, D., Bernabe Caro, R., Perez Parente, D., Moll, B., Lavara Sanz, J., Olson, S., García González, J.

Get full text

1050P Sensitization to immunotherapy through manipulation of tumor transcription by lurbinectedin by Russo-Cabrera, J.S., Ponce Aix, S., Cozar, P., Luengo, A., Navarro Mendivil, A.F., Bernabe Caro, R., Olmedo Garcia, M.E., Trigo Perez, J.M., Zugazagoitia, J., Paz-Ares, L., Otano Andres, I.

Get full text

1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC) by Remon Masip, J., Girard, N., Bironzo, P., Novello, S., De Castro Carpeno, J., Bigay-Game, L., Bernabe Caro, R., Greillier, L., Mosquera Martinez, J., Cousin, S., Juan Vidal, O.J., Sampayo-Cordero, M., Besse, B.

Get full text

1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain by Nadal, E., Fernandez, C. Alvarez, Arasanz, H., Muñoz, S. Peralta, Quintela, M. Lázaro, Teixido, C., Calvo de Juan, V., Alvarez, R.M., Espinar, J. Baena, Valdivia-Bautista, J., Arriola, E., Lastra, R., Caro, R. Bernabe, Camacho, C., Cordellat, A. Blasco, Sureda, B. Massuti, Guillaumes, M. Campayo, Dols, M. Cobo, Manrique, T. Garcia, Marquez, G.J.

Get full text

LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6 by Garassino, M.C., Mazieres, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., Cove-Smith, L.S., Mansy, T., Cortinovis, D.L., Migliorino, M.R., Delmonte, A., García Sanchez, J., Chara Velarde, L.E., Bernabe Caro, R., Paz-Ares, L., Chander, P., Diaz Perez, I., Foroutanpour, K., Faivre-Finn, C.

Get full text

1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2 by Shu, C.A., Goto, K., Ohe, Y., Besse, B., Park, K., Wang, Y., Griesinger, F., Yang, J.C-H., Felip, E., Sanborn, R.E., Caro, R. Bernabe, Bauml, J.M., Chen, J., Fennema, E., Mahoney, J., Trani, L., Knoblauch, R.E., Thayu, M., Cho, B.C.

Get full text

1010P Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics by Ruiz de Garibay, G., Roch, B., Garrido Lopez, P., Isla, D., Aguado, C., Callejo Perez, A., Marse Fabregat, R., Garcia Campelo, M.R., Blasco Cordellat, A., Sanchez Torres, J.M., Bernabe Caro, R., Juan Vidal, O.J., De Castro Carpeno, J., Franco, F.F., Ramos Garcia, I., Gomez Rueda, A., Conde Gallego, E., Ponce Aix, S., Paz-Ares, L., Zugazagoitia, J.

Get full text

939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial by Casarrubios, M., Cruz-Bermudez, A., Sierra-Rodero, B., Martinez, C., Nadal, E., Insa Molla, M.A., Martinez, J. Mosquera, Ojea, C. Gonzalez, Gomez, M. Domine, Tarruella, M. Majem, Abreu, D. Rodriguez, Martinez-Marti, A., De Castro Carpeno, J., Dols, M. Cobo, Vivanco, G. Lopez, Caro, R. Bernabe, Segarra, N. Vinolas, Aranda, I.C. Barneto, Sureda, B. Massuti, Pulla, M. Provencio

Get full text

LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial by Masip, J. Remon, Besse, B., Aix, S. Ponce, Callejo, A., Al-Rabi, K., Caro, R. Bernabe, Greillier, L., Tarruella, M. Majem, Aransay, N. Reguart, Monnet, I., Cousin, S., Lopez, P. Garrido, Robinet, G., Campelo, M.R. Garcia, Flandin, A-C. Madroszyk, Mazieres, J., Pretzenbacher, Y., Fournier, B., Dingemans, A-M.C., Dziadziuszko, R.

Get full text

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status by Ramalingam, S.S., Balli, D., Ciuleanu, T-E., Pluzanski, A., Lee, J-S., Schenker, M., Bernabe Caro, R., Lee, K.H., Bartolucci, R., Audigier-Valette, C., Hellmann, M.D., Paz-Ares, L.G., Reck, M., Borghaei, H., Brahmer, J.R., O’Byrne, K., Tran, P., Spires, T., Geese, W.J., Agrawal, S.

Get full text

122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1 by Reck, M., Ciuleanu, T.E., Pluzanski, A., Lee, J.S., Bernabe Caro, R., Linardou, H., Burgers, J., Gallardo, C., Nishio, M., Peters, S., Paz-Ares, L.G., Hellmann, M.D., Borghaei, H., Ramalingam, S.S., O’Byrne, K., Hu, N., Bushong, J., Eccles, L., Grootendorst, D., Brahmer, J.R.

Get full text

1168P Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR) by Franco, F.F., Carcereny, E., Castro, R. Lopez, Rodriguez, D., Dols, M.A. Cobo, Caro, R. Bernabe, Cordellat, A. Blasco, Sureda, B. Massuti, Granados, A.L. Ortega, Barco, E. del, Bosch-Barrera, J., Guirado, M., Gonzalez-Larriba, J.L., Vidal, O. Juan, Martinez, J. Mosquera, Rodriguez, J.M. Oramas, Gonzalez, M.A. Sala, Calvo, V., Gonzalez, A. Estival, Provencio, M.

Get full text

1730P Cancer long survivor artificial intelligence follow-up (CLARIFY): Family history of cancer and lung cancer by Calvo, V., Niazmand, E., Carcereny, E., Jozashoori, S., Rodriguez, D., Castro, R. Lopez, Guirado, M., Camps, C.J., Caro, R. Bernabe, Granados, A.L. Ortega, Sureda, B. Massuti, Dols, M.A. Cobo, Campelo, M.R. Garcia, Barco, E. del, Bosch-Barrera, J., Gonzalez-Larriba, J.L., Moran, T., Collazo, A., Vidal, M.E., Provencio, M.

Get full text

Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial by Camerini, A., Morabito, A., Montanino, A., Bernabe Caro, R., Grossi, F., Ramlau, R., Ciuleanu, T.-E., Ceresoli, G.L., Pasello, G., de Marinis, F., Bosch-Barrera, J., Landreau, P., Gautier, S., Ta Thanh Minh, C., Kowalski, D.

Get full text

1380P Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study) by Franco, F., Costa, E. Carcereny, Rodriguez-Abreu, D., Castro, R. Lopez, Dols, M. Cobo, Guirado, M., Sureda, B. Massuti, Granados, A.L. Ortega, Campelo, R. Garcia, Juan-Vidal, O., Cordellat, A. Blasco, Morillo, E. del Barco, Caro, R. Bernabe, Bosch-Barrera, J., Gonzalez-Larriba, J.L., Gonzalez, M.A. Sala, Perez, J.M. Trigo, Rodriguez, J.M. Oramas, Estival, A., Pulla, M. Provencio

Get full text